Tochigi, Japan

Yoshikazu Asahina




Average Co-Inventor Count = 3.6

ph-index = 4

Forward Citations = 28(Granted Patents)


Company Filing History:


Years Active: 1999-2016

Loading Chart...
Loading Chart...
Loading Chart...
14 patents (USPTO):Explore Patents

Title: The Innovations of Yoshikazu Asahina

Introduction

Yoshikazu Asahina is a prominent inventor based in Tochigi, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with hypoglycemic effects. With a total of 14 patents to his name, Asahina's work has the potential to impact the treatment and prevention of diabetes and obesity.

Latest Patents

One of Asahina's latest patents involves a cyclopentylacrylamide derivative. This compound is designed to have a hypoglycemic effect and is useful for treating or preventing diabetes and obesity. The compound is represented by a specific general formula, where the components can vary, including hydrogen atoms, halogen atoms, and various functional groups. This innovative approach highlights Asahina's commitment to addressing critical health issues through his inventions.

Career Highlights

Throughout his career, Yoshikazu Asahina has worked with notable companies such as Kyorin Pharmaceutical Co., Ltd. and Teijin Pharma Limited. His experience in these organizations has allowed him to refine his skills and contribute to significant advancements in pharmaceutical research and development.

Collaborations

Asahina has collaborated with esteemed colleagues, including Yasumichi Fukuda and Koji Murakami. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Yoshikazu Asahina's contributions to the field of pharmaceuticals through his innovative patents demonstrate his dedication to improving health outcomes. His work continues to pave the way for advancements in the treatment of diabetes and obesity.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…